Tales of the Unsurprised: Brand-Name Drug Prices Fell for the Fourth Consecutive Year

Tales of the Unsurprised: Brand-Name Drug Prices Fell for the Fourth Consecutive Year

Source: 
Drug Channels
snippet: 

Reality has again failed to cooperate with the politically motivated cries of “skyrocketing drug prices” or anecdotes about companies “jacking up prices” (as President Biden recently claimed).

Brand-name drug prices continue to decline, while the prices of other healthcare products and services continue to rise. For 2021, brand-name drugs’ net prices dropped for the fourth consecutive year. Meanwhile, brand-name drug list prices grew more slowly than overall inflation. What’s more, we project that the gross-to-net bubble for patent-protected brand-name drugs will exceed $200 billion in 2021. See our updated analysis below.